Literature DB >> 2229321

Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly.

U Plöckinger1, D Dienemann, H J Quabbe.   

Abstract

Gastrointestinal side-effects of prolonged therapy (greater than 2 yr) with the long-acting somatostatin analog octreotide were studied in 10 acromegalic patients. After 2 yr of therapy, 6 of 10 patients had newly developed gallstones, complicated by cholangitis and jaundice in 1. Serum vitamin B-12 concentrations declined in all 10 patients [from 380 +/- 32 to 172 +/- 21 pmol/L (mean +/- SE); P = 0.023] and became abnormally low in 4. Gastric biopsy specimens, obtained during gastroscopy (9 patients), showed moderate to severe active gastritis, with damage to the superficial and deeper layers of the mucosa in 9 of 9 and focal atrophy in 7 of 9 patients. Campylobacter pylori was found in the antral mucosa in 8 of 9 patients. Although information is lacking on similar studies in untreated acromegalic patients, we suggest that patients receiving chronic octreotide therapy be closely monitored for these and possible other side-effects related to gastrointestinal actions of octreotide.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2229321     DOI: 10.1210/jcem-71-6-1658

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  Treatment options in acromegaly. Benefits and costs.

Authors:  L M Weekes; K K Ho; J P Seale
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

2.  Sphincterotomy and the gall bladder--a slice of luck.

Authors:  L J O'Donnell
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

3.  The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system.

Authors:  Serdar Sahin; Tevhide Betul Icli; Emre Durcan; Cem Sulu; Hande Mefkure Ozkaya; Ali Ibrahim Hatemi; Pinar Kadioglu
Journal:  Pituitary       Date:  2020-10-19       Impact factor: 4.107

4.  Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly.

Authors:  L A Thomas; M J Veysey; G M Murphy; D Russell-Jones; G L French; J A H Wass; R H Dowling
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

Review 5.  Gall stones and gall bladder motility.

Authors:  L J O'Donnell; P D Fairclough
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

6.  Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.

Authors:  R Attanasio; A Mainolfi; F Grimaldi; R Cozzi; M Montini; C Carzaniga; S Grottoli; L Cortesi; M Albizzi; R M Testa; L Fatti; D De Giorgio; C Scaroni; F Cavagnini; P Loli; G Pagani; E Ghigo
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

Review 7.  Use of octreotide acetate for control of symptoms in patients with islet cell tumors.

Authors:  P N Maton
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

8.  Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegaly.

Authors:  U Plöckinger; H J Quabbe
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

Review 9.  Drug-induced gallbladder disease. Incidence, aetiology and management.

Authors:  P P Michielsen; H Fierens; Y M Van Maercke
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

10.  Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly.

Authors:  S M Catnach; J V Anderson; P D Fairclough; R C Trembath; P A Wilson; E Parker; G M Besser; J A Wass
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.